PTH and hypoparathyroidism: Although the U.S. Food and Drug Administration approved recombinant human PTH (1–84) for managing hypoparathyroidism, high-dose calcium and active vitamin D has been the main hypoparathyroidism treatment in most countries, generating concerns for unwanted complications of hypercalciuria, renal stones, impaired renal function, and cardiovascular disease (CVD) [1].